For the quarter ending 2025-09-30, CBIO has $138,269K in assets. $21,628K in debts. $133,265K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 133,265 | - | ||
| Prepaid expenses and other current assets | 1,298 | 1,582 | ||
| Cash | - | 152,645 | ||
| Total current assets | 134,563 | 154,227 | ||
| Property and equipment, net | 782 | 193 | ||
| Operating lease right-of-use assets | 1,564 | 1,607 | ||
| Restricted cash | 107 | 106 | ||
| Other assets | 1,253 | 1,300 | ||
| Total assets | 138,269 | 157,433 | ||
| Accounts payable-Nonrelated Party | 2,561 | 1,648 | ||
| Accrued expenses and other current liabilities-Nonrelated Party | 8,965 | 7,608 | ||
| Related party accounts payable and other current liabilities-Related Party | 6,273 | 5,183 | ||
| Operating lease liability, current | 417 | 211 | ||
| Warrant liability, related party | 2,088 | 2,096 | ||
| Total current liabilities | 20,304 | 16,746 | ||
| Operating lease liability, noncurrent | 1,324 | 1,433 | ||
| Notes payable, noncurrent | 0 | 0 | ||
| Total liabilities | 21,628 | 18,179 | ||
| Series a non-voting convertible preferred shares, 0.001 par value 5,000,000 shares and no shares authorized as of september 30, 2025 and december 31, 2024, respectively 2,890 shares and no shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively-Series APreferred Stock | 4,000 | 4,000 | ||
| Ordinary shares, 0.001 par value 175,000,000 and 40,000,000 shares authorized as of september 30, 2025 and december 31, 2024, respectively, 13,892,562 and 1,018,604 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 14 | 14 | ||
| Additional paid-in capital | 192,039 | 190,045 | ||
| Accumulated deficit | -79,412 | -54,805 | ||
| Total shareholders' equity (deficit) | 116,641 | 139,254 | ||
| Total liabilities, convertible preferred shares, and shareholders equity (deficit) | 138,269 | 157,433 | ||
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)